title: cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance.
abstract: In the last decade, the tyrosine kinase receptor cMET, together with its ligand hepatocyte growth factor (HGF), has become a target in non-small cell lung cancer (NSCLC). Signalization via cMET stimulates several oncological processes amongst which are cell motility, invasion and metastasis. It also confers resistance against several currently used targeted therapies, e.g., epidermal growth factor receptor (EGFR) inhibitors. In this review, we will discuss the basic structure of cMET and the most important signaling pathways. We will also look into aberrations in the signaling and the effects thereof in cancer growth, with the focus on NSCLC. Finally, we will discuss the role of cMET as resistance mechanism.
authors: Center for Oncological Research Antwerp, University of Antwerp, Universiteitsplein 1, Wilrijk 2610, Belgium. Nele.VanDerSteen@uantwerpen.be.
authors: Nele
authors: N
authors: Van Der Steen
authors: Center for Oncological Research Antwerp, University of Antwerp, Universiteitsplein 1, Wilrijk 2610, Belgium. Patrick.Pauwels@uza.be.|Molecular Pathology Unit, Pathology Department, Antwerp University Hospital, Wilrijkstraat 10, Edegem 2650, Belgium. Patrick.Pauwels@uza.be.
authors: Patrick
authors: P
authors: Pauwels
authors: Department of Oncology, Clínica Universidad de Navarra, Pamplona 31008, Spain.
authors: Ignacio
authors: I
authors: Gil-Bazo
authors: Department of Oncology, Clínica Universidad de Navarra, Pamplona 31008, Spain. ecastanon@unav.es.|Phase I-Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital, Wilrijkstraat 10, Edegem 2650, Belgium. ecastanon@unav.es.
authors: Eduardo
authors: E
authors: Castañon
authors: Thoracic Oncology Program, Memorial Cancer Institute, Memorial Health Care System, Pembroke Pines, FL 33024, USA. lraez@mhs.net.
authors: Luis
authors: L
authors: Raez
authors: Medical Oncology Department, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy viale Alfieri 36, Livorno 57100, Italy. f.cappuzzo@gmail.com.
authors: Federico
authors: F
authors: Cappuzzo
authors: Center for Oncological Research Antwerp, University of Antwerp, Universiteitsplein 1, Wilrijk 2610, Belgium. Christian.Rolfo@uza.be.|Phase I-Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital, Wilrijkstraat 10, Edegem 2650, Belgium. Christian.Rolfo@uza.be.
authors: Christian
authors: C
authors: Rolfo